ALLO Allogene Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737287 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-26.7%
TTM net income YoY22.1%
TTM EPS YoY36.8%
Revenue 3-yr CAGR-91.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,241,813.6%
Net margin-1,170,863.6%
FCF margin-913,609.1%
EBITDA margin-1,179,818.2%
Returns
ROE-55.1%
ROA-43.2%
ROIC (approx.)-57.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.1%
Debt / equity0.00x
Current ratio8.54x
Interest coverage-1,509.39x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue3,154.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $22,000 | $95,000 | $156,000 | $114.09M |
| R&D expense | $150.15M | $192.30M | $242.91M | $256.39M | $220.18M |
| SG&A expense | $56.78M | $65.20M | $71.67M | $79.31M | $74.11M |
| Operating income | -$209.31M | -$273.20M | -$327.74M | -$335.54M | -$180.19M |
| Interest expense | $1.07M | $181,000 | $0 | — | — |
| Pretax income | -$190.89M | -$257.15M | -$327.26M | — | -$257.00M |
| Income tax | $0 | $443,000 | $0 | $0 | $0 |
| Net income | -$190.89M | -$257.59M | -$327.26M | -$340.41M | -$182.05M |
| EBITDA | -$196.96M | -$259.56M | -$313.54M | -$321.24M | -$169.69M |
| EPS (basic) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| EPS (diluted) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M |
| Balance sheet | |||||
| Cash & equivalents | $51.69M | $85.51M | $93.45M | $72.20M | $183.61M |
| Short-term investments | $198.52M | $217.26M | $365.54M | $455.42M | $283.99M |
| Current assets | $257.75M | $303.39M | $459.12M | $528.82M | $471.32M |
| PP&E, net | $72.84M | $86.06M | $99.48M | $112.84M | $122.99M |
| Total assets | $415.90M | $548.71M | $642.84M | $821.58M | $1.05B |
| Current liabilities | $32.51M | $35.52M | $37.08M | $53.73M | $47.91M |
| Total liabilities | $123.36M | $126.53M | $130.60M | $154.70M | $125.63M |
| Shareholders' equity | $292.54M | $422.18M | $512.23M | $666.88M | $925.20M |
| Shares outstanding | 229.41M | 212.21M | 168.64M | 144.44M | 142.62M |
| Cash flow statement | |||||
| Operating cash flow | -$149.25M | -$200.30M | -$237.73M | -$220.52M | -$184.81M |
| Capital expenditure | $386,000 | $694,000 | $1.52M | $5.19M | $21.45M |
| Free cash flow | -$149.63M | -$200.99M | -$239.25M | -$225.71M | -$206.26M |
| Investing cash flow | $95.56M | $75.69M | $163.29M | $106.16M | $163.66M |
| Financing cash flow | $30.16M | $116.67M | $95.69M | $2.95M | $11.96M |
| Depreciation & amortization | $12.36M | $13.64M | $14.20M | $14.30M | $10.50M |
| Stock-based compensation | $37.64M | $51.74M | $65.95M | $83.60M | $80.82M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.